Cargando…

Prevalence of IGLV3-21(R110) among familial CLL: a retrospective study of 45 cases

Detalles Bibliográficos
Autores principales:	Armand, Marine, Verrier, Patricia, Theves, Floriane, Bravetti, Clotilde, Le Garff-Tavernier, Magali, Choquet, Sylvain, Davi, Frédéric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631562/ https://www.ncbi.nlm.nih.gov/pubmed/35294518 http://dx.doi.org/10.1182/bloodadvances.2021006658

Ejemplares similares

Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21(R110) chronic lymphocytic leukemia
por: Paschold, Lisa, et al.
Publicado: (2022)

IGLV3-21*01 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling
por: Maity, Palash C., et al.
Publicado: (2020)

Prognosis of IGLV3-21(R110) chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis
por: Hengeveld, Paul J., et al.
Publicado: (2023)

Successful treatment of an EBV‐positive HIV‐associated polymorphic B‐cell lymphoproliferative disorder by rituximab monotherapy
por: Sabbah, Mohamad, et al.
Publicado: (2021)

Leptomeningeal involvement in CLL
por: Chantepie, Sylvain P., et al.
Publicado: (2014)

CD160 receptor in CLL: Current state and future avenues
por: Oumeslakht, Loubna, et al.
Publicado: (2022)

5H-Imidazo[4,5-f][1,10]phenanthroline
por: Tong, Shao-Wei, et al.
Publicado: (2012)

Inflammation in Waldenström macroglobulinemia is associated with 6q deletion and need for treatment initiation
por: Forgeard, Nathalie, et al.
Publicado: (2022)

Bis(imidazo[4,5-f][1,10]phenanthroline)dinitratolead(II)
por: Li, Chun-Xiang, et al.
Publicado: (2008)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial
por: Michallet, Anne-Sophie, et al.
Publicado: (2023)

NF45 and NF90/NF110 coordinately regulate ESC pluripotency and differentiation
por: Ye, Julia, et al.
Publicado: (2017)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity
por: Sofou, Electra, et al.
Publicado: (2022)

1,2-Diphenyl-1H-imidazo[4,5-f][1,10]phenanthroline
por: Rosepriya, S., et al.
Publicado: (2011)

1,10-Phenanthrolin-1-ium 2-carboxy-4,5-dichlorobenzoate
por: Smith, Graham, et al.
Publicado: (2009)

Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL
por: Agathangelidis, Andreas, et al.
Publicado: (2022)

Significance of t (8: 14) in CLL?
por: Lakshmaiah, K. C., et al.
Publicado: (2010)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

Tumor suppressors revival in CLL
por: Carrà, Giovanna, et al.
Publicado: (2017)

CLL und Covid-19
por: Behrend, Christian
Publicado: (2022)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL
por: Nichols, Eva-Maria, et al.
Publicado: (2015)

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
por: Quinquenel, Anne, et al.
Publicado: (2020)

1H-Imidazo[4,5-f][1,10]phenanthrolin-7-ium perchlorate monohydrate
por: Shen, Su-Mei
Publicado: (2009)

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC
por: Decker, William K., et al.
Publicado: (2012)

Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
por: Heyman, B, et al.
Publicado: (2016)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

CD47 Agonist Peptides Induce Programmed Cell Death in Refractory Chronic Lymphocytic Leukemia B Cells via PLCγ1 Activation: Evidence from Mice and Humans
por: Martinez-Torres, Ana-Carolina, et al.
Publicado: (2015)

CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes
por: Lacan, Claire, et al.
Publicado: (2023)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Critical molecular pathways in CLL therapy
por: Ferrer, Gerardo, et al.
Publicado: (2018)

Reactivating nuclear PTEN to treat CLL
por: Bernardi, Rosa, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bcnlk25ih1u9rrabag6grif3gd